Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits

Abstract

Although all assays are suitable for TDM, significant differences were observed in both imprecision and agreement. Therapeutic consequences were acceptable when patients were divided in treatment categories, but this could be improved by assay standardization.